JP2015518855A - 粘膜炎の治療のための組成物および方法 - Google Patents

粘膜炎の治療のための組成物および方法 Download PDF

Info

Publication number
JP2015518855A
JP2015518855A JP2015513324A JP2015513324A JP2015518855A JP 2015518855 A JP2015518855 A JP 2015518855A JP 2015513324 A JP2015513324 A JP 2015513324A JP 2015513324 A JP2015513324 A JP 2015513324A JP 2015518855 A JP2015518855 A JP 2015518855A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administration
independently
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015513324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518855A5 (https=
Inventor
カンデュラ，マヘシュ
Original Assignee
セリックスビオ プライヴェート リミテッド
セリックスビオ プライヴェート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セリックスビオ プライヴェート リミテッド, セリックスビオ プライヴェート リミテッド filed Critical セリックスビオ プライヴェート リミテッド
Publication of JP2015518855A publication Critical patent/JP2015518855A/ja
Publication of JP2015518855A5 publication Critical patent/JP2015518855A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
JP2015513324A 2012-05-23 2013-05-19 粘膜炎の治療のための組成物および方法 Pending JP2015518855A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2057/CHE/2102 2012-05-23
IN2057CH2012 2012-05-23
PCT/IB2013/054098 WO2013175377A2 (en) 2012-05-23 2013-05-19 Compositions and methods for the treatment of mucositis

Publications (2)

Publication Number Publication Date
JP2015518855A true JP2015518855A (ja) 2015-07-06
JP2015518855A5 JP2015518855A5 (https=) 2015-08-20

Family

ID=53097332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513324A Pending JP2015518855A (ja) 2012-05-23 2013-05-19 粘膜炎の治療のための組成物および方法

Country Status (9)

Country Link
US (2) US9765020B2 (https=)
EP (1) EP2852571A4 (https=)
JP (1) JP2015518855A (https=)
CN (1) CN104583182A (https=)
AU (1) AU2013264820A1 (https=)
CA (1) CA2873104A1 (https=)
SG (1) SG11201407326XA (https=)
WO (1) WO2013175377A2 (https=)
ZA (1) ZA201408056B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501969A (ja) * 2015-12-16 2019-01-24 ニューロフィシア・ベー・フェー 脳細胞傷害の処置における使用のための２−イミノビオチン

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014091384A2 (en) * 2012-12-12 2014-06-19 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN105963799A (zh) * 2016-06-16 2016-09-28 湖州科达化工燃料有限公司 一种抗感染的防粘连膜
SG11202103180QA (en) * 2018-10-17 2021-05-28 Lakewood Amedex Inc Methods and compositions for treating oral mucositis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4828434A (https=) * 1971-06-02 1973-04-14 Seperic
CA1081709A (en) * 1975-07-11 1980-07-15 Julius Diamond Phenylamidino urea compounds
JP2004513957A (ja) * 2000-11-22 2004-05-13 アールエックスキネティックス，インコーポレイテッド 粘膜炎の治療
JP2008534471A (ja) * 2005-03-24 2008-08-28 ロッタファルム・ソシエタ・ペル・アチオニ 癌療法性粘膜炎の治療および予防のためのベンズアミジン誘導体

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2807644A (en) 1954-08-20 1957-09-24 Parke Davis & Co Pantethine inhibitors
DE1205972B (de) 1963-08-20 1965-12-02 Merck Ag E Verfahren zur Herstellung eines Liponsaeure-derivates
US4011342A (en) * 1971-06-02 1977-03-08 Seperic Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines
JPS5677259A (en) 1979-11-29 1981-06-25 Nippon Chemiphar Co Ltd N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation
JPS57500432A (https=) 1980-03-20 1982-03-11
US4404366A (en) 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
IT1190727B (it) 1982-03-10 1988-02-24 Ausonia Farma Srl Composto ad attivita' analgesica,antiinfiammatoria e mucoregolatrice procedimento per la sua preparazione e relative composizioni farmaceutiche
FR2528038B2 (fr) 1982-06-04 1985-08-09 Lafon Labor Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique
US4564628A (en) 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5104887A (en) 1983-02-04 1992-04-14 University Of Iowa Research Foundation Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
JPS6089474A (ja) 1983-10-20 1985-05-20 Toyo Pharma- Kk モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
IL73293A (en) 1983-11-04 1988-02-29 Abbott Lab Methyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives
IT1213132B (it) 1984-02-02 1989-12-14 Yason Srl Agente antibroncopneumopatico.
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5120738A (en) 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
US5242937A (en) 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
IT1248702B (it) 1990-06-06 1995-01-26 Yason Srl Agente antitussivo e mucoregolatore,sua preparazione e composizioni farmaceutiche
FR2699077B1 (fr) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2707637B1 (fr) 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
SE9401727D0 (sv) 1994-05-18 1994-05-18 Astra Ab New compounds I
FR2722199B3 (fr) 1994-07-11 1996-09-06 Univ Picardie Jules Verne Etab Derives de l'acide valproique et leurs applications comme medicaments
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
KR20000069075A (ko) 1996-11-22 2000-11-25 진 엠. 듀발 Ｎ-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
NZ506574A (en) 1998-02-27 2003-06-30 Sankyo Co Cyclic amino derivative having a sulphinyl, sulphonyl or disulphanyl group useful in the treatment of thrombosis or embolism
JP3761324B2 (ja) 1998-05-15 2006-03-29 ヤンマー農機株式会社 乗用田植機
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
DE60039132D1 (de) 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CA2385990A1 (en) 1999-09-29 2001-04-05 The Procter & Gamble Company Compositions having improved stability
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
CA2426745C (en) 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Methods for producing nateglinide b-type crystals
DE10103506A1 (de) 2001-01-26 2002-08-14 Ingo S Neu Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2003018004A2 (en) 2001-08-29 2003-03-06 Endo Pharmaceuticals, Inc. Analgetic pyrroline derivatives
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
JP4615866B2 (ja) 2002-04-15 2011-01-19 ノバルティス アーゲー Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
MXPA04010170A (es) 2002-04-16 2005-02-03 Fujisawa Pharmaceutical Co Medicamento para prevenir y/o tratar el rechazo cronico.
US7060725B2 (en) 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
GB0223224D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
ES2310715T3 (es) 2003-02-14 2009-01-16 Pierre Fabre Medicament Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento.
UA81657C2 (ru) 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Способ получения противосудорожных производных топирамата
CN101123878A (zh) 2003-07-29 2008-02-13 信号研发控股有限责任公司 氨基酸前药
PT1677767E (pt) 2003-10-14 2011-10-13 Xenoport Inc Forma cristalina de análogo de ácido gama-aminobutírico
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
RU2346935C2 (ru) 2003-11-28 2009-02-20 Санкио Компани, Лимитед Производное циклического амина, содержащее гетероарильный цикл
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
CN1248690C (zh) 2004-03-25 2006-04-05 华中师范大学 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂
WO2005116086A2 (en) 2004-04-07 2005-12-08 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
BRPI0510428A (pt) 2004-04-29 2007-10-30 Caldwell Galer Inc composições tópicas de metadona e processos para utilização das mesmas
CN1672678A (zh) 2004-05-03 2005-09-28 深圳微芯生物科技有限责任公司 预防和治疗前列腺疾病的长链脂肪酸天然活性成分的分离、提取和药用制剂的制备和应用
RU2365580C2 (ru) 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
CN100455560C (zh) 2004-06-09 2009-01-28 中国人民解放军军事医学科学院放射医学研究所 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途
AU2006225005A1 (en) 2005-03-18 2006-09-21 Ripped Formulations Ltd. Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
JP2008540486A (ja) 2005-05-11 2008-11-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物
DE102005022276A1 (de) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
EP1889835A4 (en) 2005-05-27 2010-04-28 Daiichi Sankyo Co Ltd CYCLIC AMINE DERIVATIVE WITH SUBSTITUTED ALKYL GROUP
US20080262053A1 (en) 2005-10-18 2008-10-23 Juergen Reess Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls)
JPWO2007086493A1 (ja) 2006-01-27 2009-06-25 旭化成ファーマ株式会社 経鼻投与用薬剤
WO2007121188A2 (en) 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
US7943666B2 (en) 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
DK2101766T3 (en) 2006-12-14 2017-01-16 Knopp Biosciences Llc Compositions and Methods for Using (R) -Pramipexole
CN100573950C (zh) 2006-12-14 2009-12-23 财团法人工业技术研究院 相变存储装置及其制造方法
AU2007338631A1 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CA2675134A1 (en) 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Pterin analogs
ES2319024B1 (es) 2007-02-13 2009-12-11 Quimica Sintetica, S.A. Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina.
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US7973049B2 (en) 2007-05-01 2011-07-05 Concert Pharmaceuticals Inc. Morphinan compounds
EP1997493A1 (en) 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Combination of a 5-HT7 receptor ligand and an opioid receptor ligand
EP2190853A4 (en) 2007-06-22 2011-08-31 Gluconova Llc HALOGENIDE-FREE COMPLEXES FROM GLUCOSAMINE AND AN ACIDIC ACID
US20090075942A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fosamprenavir
CN101390854A (zh) 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 一种含有利鲁唑的药用组合物
WO2009056791A1 (en) 2007-11-02 2009-05-07 Pliva Hrvatska D.O.O. Processes for preparing pharmaceutical compounds
US20090118365A1 (en) 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
CN101186583B (zh) 2007-12-20 2011-05-11 吉林大学 2-(2-(2,6-二氯苯基氨基)苯基)醋酸甲酯及其合成方法及其应用
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
CN102512405B (zh) 2008-04-30 2015-08-05 上海医药工业研究院 一类长链脂肪酸衍生物或含其的植物提取物在制备抑制芳香化酶活性的药物中的应用
KR100990949B1 (ko) 2008-06-09 2010-10-29 엔자이텍 주식회사 클로피도그렐 및 그의 유도체의 제조방법
EP2315740B1 (en) 2008-07-08 2017-10-25 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
RU2540465C2 (ru) 2008-08-22 2015-02-10 Вокхардт Рисерч Сентер Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения
WO2010073124A2 (en) 2008-12-26 2010-07-01 Actavis Group Ptc Ehf Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
BRPI0901298A2 (pt) 2009-04-06 2011-01-04 Ems Sa derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
WO2011017800A1 (en) 2009-08-10 2011-02-17 Bellus Health (International) Limited Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
CN102002053A (zh) 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
CN101717392A (zh) 2009-10-09 2010-06-02 苏州凯达生物医药技术有限公司 一种制备罗替戈汀及其衍生物的方法
CN102050815B (zh) 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 作为前药的达比加群的酯衍生物
CN101724934B (zh) 2009-11-10 2012-07-04 东华大学 一种用于治疗皮肤炎症和疼痛的药用纤维及其制备和应用
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
JP5771627B2 (ja) 2010-01-08 2015-09-02 カタバシス ファーマシューティカルズ，インコーポレイテッド 脂肪酸フマル酸塩誘導体およびそれらの使用
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
RU2436772C2 (ru) 2010-01-28 2011-12-20 Закрытое акционерное общество "НПК ЭХО" 4[(4'-никотиноиламино)бутироиламино]бутановая кислота, проявляющая ноотропную активность, и способ ее получения
WO2011106688A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
BR112012031194A2 (pt) 2010-06-08 2018-05-29 Krisani Biosciences P Ltd derivados de cisteamina e seu uso no tratamento de ehna
PH12013500081B1 (en) 2010-07-12 2017-09-27 Boehringer Ingelheim Int Aqueous composition comprising bromhexine
AR082499A1 (es) 2010-08-23 2012-12-12 Gruenenthal Gmbh Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
CN101921245B (zh) 2010-08-30 2012-04-18 中国人民解放军军事医学科学院卫生学环境医学研究所 抑制碳酸酐酶ⅱ的磺胺类化合物及合成方法与用途
ES2655084T3 (es) 2010-10-29 2018-02-16 Algiax Pharmaceuticals Gmbh Empleo de malononitrilamidas en dolor neuropático
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2013008182A1 (en) 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
CN102336767A (zh) 2011-07-11 2012-02-01 华东理工大学 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法
WO2013017974A1 (en) 2011-07-30 2013-02-07 Mahesh Kandula Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013024376A1 (en) 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
WO2013027150A1 (en) 2011-08-21 2013-02-28 Mahesh Kandula Compositions and methods for the treatment of parkinson's disease
CN102633799B (zh) 2012-04-10 2014-06-25 凯莱英医药集团（天津）股份有限公司 一种从消旋体中间体拆分路线合成二盐酸沙丙蝶呤的方法
US20150133533A1 (en) 2012-05-08 2015-05-14 Mahesh Kandula Compositions and methods for the treatment of cough
WO2013168022A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167996A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4828434A (https=) * 1971-06-02 1973-04-14 Seperic
CA1081709A (en) * 1975-07-11 1980-07-15 Julius Diamond Phenylamidino urea compounds
JP2004513957A (ja) * 2000-11-22 2004-05-13 アールエックスキネティックス，インコーポレイテッド 粘膜炎の治療
JP2008534471A (ja) * 2005-03-24 2008-08-28 ロッタファルム・ソシエタ・ペル・アチオニ 癌療法性粘膜炎の治療および予防のためのベンズアミジン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 18(1), JPN6016039610, 1975, pages 90 - 9, ISSN: 0003419636 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 97(10), JPN6016039608, 1975, pages 2811 - 18, ISSN: 0003419635 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501969A (ja) * 2015-12-16 2019-01-24 ニューロフィシア・ベー・フェー 脳細胞傷害の処置における使用のための２−イミノビオチン

Also Published As

Publication number Publication date
WO2013175377A3 (en) 2014-01-30
EP2852571A2 (en) 2015-04-01
SG11201407326XA (en) 2014-12-30
US9765020B2 (en) 2017-09-19
CA2873104A1 (en) 2013-11-28
US20150307446A1 (en) 2015-10-29
EP2852571A4 (en) 2015-11-25
AU2013264820A1 (en) 2014-11-27
CN104583182A (zh) 2015-04-29
ZA201408056B (en) 2016-04-28
WO2013175377A2 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
JP2015518855A (ja) 粘膜炎の治療のための組成物および方法
JP2015518855A5 (https=)
JP2015521184A (ja) メタボリック症候群の治療のための組成物と治療法
JP2016508956A (ja) 局所疼痛の治療のための組成物と治療法
AU2019214557A1 (en) Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
JP2017531649A (ja) 多発性硬化症の治療のための組成物及び方法
CN104364241A (zh) 抑制碳酸酐酶活性的组合物和方法
KR20190077383A (ko) 구강건조증(xerostomia)의 치료를 위한 조성물 및 방법
JP2020100623A (ja) 炎症及び疼痛の治療のための組成物及び方法
WO2014091384A2 (en) Compositions and methods for the treatment of mucositis
KR102567090B1 (ko) 곰팡이 감염의 치료를 위한 조성물 및 방법
US9096537B1 (en) Compositions and methods for the treatment of mucositis
JP2015519333A5 (https=)
JP2015518854A5 (https=)
JP2015518854A (ja) 多発性硬化症の治療のための組成物および方法
JP2015527309A (ja) 中等度から重度の疼痛の治療のための組成物及び方法
JP2015519334A (ja) 抗血小板薬のプロドラッグ
RU2751770C2 (ru) Композиции и способы лечения синдрома раздраженного кишечника
RU2749188C2 (ru) Композиции и способы лечения желудочно-кишечных полипов
CN104797568A (zh) 用于治疗神经障碍的组合物和方法
JP6698669B2 (ja) 粘膜炎の治療のための組成物及び方法
US20150087697A1 (en) Compositions and methods for the treatment of muscle pain
JP2018532704A (ja) パーキンソン病の治療のための組成物及び方法
NZ734324B2 (en) Compositions and methods for the treatment of inflammation and pain
WO2015008205A2 (en) Compositions and methods for the treatment of respiratory diseases

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170711